Table 2 Adverse events within 2Â months after infusion
From: A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
Adverse event | Any Grade | Grade 3 | Grade 4 |
|---|---|---|---|
Number of patients (percent) | Â | Â | Â |
CRS per Lee Criteria | 20 (87) | 2 (9) | 3 (13) |
CRS per ASTCT Consensus* | 20 (87) | 4 (17) | 0 |
CRES | 0 | 0 | 0 |
Hematologic | Â | Â | Â |
Leukopenia | 20 (87) | 6 (26) | 13 (57) |
Neutropenia | 22 (96) | 3 (13) | 17 (74) |
Anemia | 10 (43) | 3 (13) | 0 |
Thrombocytopenia | 14 (61) | 4Â (17) | 7 (30) |
Pulmonary | Â | Â | Â |
Pleural effusion | 3 (13) | 1 (4) | 0 |
Pulmonary edema | 1 (4) | 1 (4) | 0 |
Gastrointestinal | Â | Â | Â |
Diarrhea | 3 (13) | 0 | 0 |
Vomiting | 1 (4) | 0 | 0 |
Hepatic | Â | Â | Â |
AST increase | 8 (35) | 3 (13) | 0 |
ALT increase | 10 (43) | 4 (17) | 1 (4) |
Nephritic | Â | Â | Â |
Creatinine increase | 3 (13) | 0 | 1 (4) |
Infection | Â | Â | Â |
Oral candidiasis | 1(4) | 0 | 0 |
Upper respiratory tract infection | 2 (9) | 0 | 0 |
Lung infection | 1 (4) | 1 (4) | 0 |
Digestive infection | 1 (4) | 1 (4) | 0 |
Others | Â | Â | Â |
Fever | 19 (83) | 2 (9) | 0 |
Hypotension | 1 (4) | 0 | 0 |
Hypoxemia | 3 (13) | 1 (4) | 1 (4) |
Sinus tachycardia | 8 (35) | 1 (4) | 0 |
Hypocalcemia | 15 (65) | 2 (9) | 1 (4) |
Hypokalemia | 6 (26) | 0 | 0 |
Hyponatremia | 5 (22) | 0 | 0 |